ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ADXN
GELS (54) PCSA (39) SCNX (28) LGVN (27) ⌘ Pro Terminal →

Addex Therapeutics Ltd (ADXN) — RQD Stock Rating Cockpit

$2.99 -3.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.97

Addex Therapeutics Ltd (ADXN) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADXN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADXN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Addex Therapeutics Ltd (NASDAQ: ADXN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $2.99 (-3.24% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ADXN ranks #294 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADXN compare to GELS and PCSA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADXN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GELS (Gelteq Limited) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, ADXN leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADXN?
▼

For Addex Therapeutics Ltd (ADXN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #294 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.97 (-0.77%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.3% Base Target
$11 Bull$3 Base$2 Bear
📬 FREE ADXN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADXN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY ADXN SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($147.4K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$3.01+1.3% Next Q
Q2 (-2Q)
53
Grade C-$3.05-2% Next Q
Q3 (-1Q)
51
Grade C-$2.99+0% Next Q
Current
48
Grade D$2.99-5.6% Hist 90D α
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ADXN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ADXN currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.27) and Max Pain ($3.14) forces dealer call-delta covering toward $10.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADXN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADXN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
49.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE5% OF RANGE
L: $3$2.99H: $10
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ADXN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (38)

14/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ADXN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADXN)

  • ✓Walkthrough of ADXN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ADXN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.85%▼ DESCENDING CHANNEL
2026-11-03O $2.93H $3.09L $2.93C $2.99VOL 2.6K
RES: $5.06SUP: $1.34SMA50: $3.27SMA200: $5.75
$8.34$6.77$5.21$3.64$2.07RES $5.06SUP $1.34$2.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADXN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADXN Butterfly Map → + Track ADXN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ADXN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADXN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADXN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADXN)

Health Care Rank #294 of 1015 ⚔️ GELS vs ADXN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADXN vs. GELS, PCSA, SCNX, LGVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Addex Therapeutics Ltd (ADXN) ranks #294 by composite RQD confidence (48/100, grade D) and #937 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, ADXN leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ADXN at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ADXN ACTIVE
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M Benchmark Subject
GELS
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M /gels-vs-adxn →
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M /pcsa-vs-adxn →
SCNX
Scienture Holdings Inc.
E 28/100 — 76.8% -35.0% +0.31% $5.3M /scnx-vs-adxn →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% +2.40% $5.3M /lgvn-vs-adxn →

2. ADXN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Addex Therapeutics Ltd (ADXN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ADXN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADXN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Addex Therapeutics Ltd (NASDAQ: ADXN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $2.99 (-3.24% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ADXN ranks #294 in composite RQD confidence.

How does ADXN compare to GELS and PCSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADXN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GELS (Gelteq Limited) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, ADXN leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADXN?

For Addex Therapeutics Ltd (ADXN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #294 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADXN trading relative to its 50-day, 200-day, and 52-week technical levels?

ADXN last traded at $2.99 (-3.24% on volume of 2,235 shares), positioning the stock -8.56% below its 50-day simple moving average ($3.27) and -48.00% below its 200-day simple moving average ($5.75). Across its 52-week range of $2.56 to $10.43, ADXN sits at the 5.5% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.62 to $3.36).

Direct Sub-Reports: ADXN RQD Cockpit ADXN 12M Forecast ADXN Earnings & Move ADXN Dividends & DRIP ADXN Insiders & 13F ADXN Whale Options ADXN Profit Sankey ADXN News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

ADXN — Addex Therapeutics Ltd: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Addex Therapeutics Ltd (ADXN) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.99 (-3.24% 1D, market capitalization $5.3M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Addex Therapeutics Ltd (ADXN) is listed on NASDAQ in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. — for products sold, customers served, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.56 – $10.43 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector: Health Care; industry: Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can ADXN sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $10.43 52-week high?
  • Key Question #3: How sensitive is ADXN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ADXN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Addex Therapeutics Ltd (ADXN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADXN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADXN Bull vs. Bear Conversation Board — What's Your Call at $2.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADXN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ADXN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $3.62 (+17.2%)
📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20, with Altman Z 2.5 and Piotroski F 6/9) is the rating's strongest component, indicating a comp

The street is overcomplicating Addex Therapeutics Ltd (ADXN). The Forensic Balance Sheet pillar (13/20, with Altman Z 2.5 and Piotroski F 6/9) is the rating's strongest component, indicating a comparatively steadier balance sheet.. With an RQD score of 48/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $3.34.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.63 (-14.9%)
Spot @ $3.09

The rating's 3/20 Whale 13F Flow pillar and 0% ROIC and FCF yield show weak institutional support and no current cash-return evidence.

The rating's 3/20 Whale 13F Flow pillar and 0% ROIC and FCF yield show weak institutional support and no current cash-return evidence.. Look at the math on ADXN: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.72 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%